Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

INTRODUCTION: Chimeric Antigen Receptor (CAR)-T cell therapy is a form of adoptive cell therapy that has demonstrated tremendous results in the treatment of hematopoietic malignancies, leading to the US Food and Drug Administration (FDA) approval of four CD19-targeted CAR-T cell products. With the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Drougkas, Konstantinos, Karampinos, Konstantinos, Karavolias, Ioannis, Koumprentziotis, Ioannis-Alexios, Ploumaki, Ioanna, Triantafyllou, Efthymios, Trontzas, Ioannis, Kotteas, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129996/
https://www.ncbi.nlm.nih.gov/pubmed/36564524
http://dx.doi.org/10.1007/s00432-022-04547-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129996/
https://www.ncbi.nlm.nih.gov/pubmed/36564524
http://dx.doi.org/10.1007/s00432-022-04547-4

Ejemplares similares